\-\ Texto\\:\\ \ \(0\)\
\-\ bilateral\\ mastectomy\\ was\\ advised\\.\ \(0\)\
\-\ bilateral\\ circumscribed\\ masses\\,\\ the\\ mass\\ on\\ left\\ is\\ associated\\ with\\ pleomorphic\\ calcifications\\.\ \(0\)\
\-\ bilateral\\ breast\\ carcinoma\ \(0\)\
\-\ fibroadenoma\ \(22\)\
\-\ cysts\ \(539\)\
\-\ malignancy\\ \\(primary\\ or\\ metastatic\\)\ \(1\)\
\-\ asymptomatic\\.\ \(81\)\
\-\ pathologic\\ diagnosis\\ on\\ both\\ left\\ and\\ right\\ side\\:\\ papillary\\ carcinoma\\ in\\ situ\\,lobular\\ carcinoma\\ and\\ ductal\\ carcinoma\\ in\\ situ\\.\\ \\ \ \(0\)\
\-\ the\\ patient\\ in\\ the\\ above\\ case\\ has\\ elected\\ to\\ have\\ breast\\ conserving\\ therapy\\,\\ despite\\ recommendation\\ for\\ bilateral\\ mastectomy\\.\\ \ \(0\)\
\-\ in\\ a\\ recent\\ study\\ based\\ in\\ the\\ netherlands\\*\\,\\ patients\\ with\\ synchronous\\ breast\\ cancer\\ \\(defined\\ as\\ bilateral\\ breast\\ cancer\\ \\â\\€\\“\\ bbc\\ \\-\\ cancer\\ diagnosed\\ in\\ both\\ breasts\\ at\\ the\\ same\\ time\\ or\\ within\\ a\\ period\\ of\\ 3\\ months\\ of\\ diagnosis\\ of\\ the\\ first\\ tumor\\)\\ had\\ a\\ worse\\ prognosis\\ and\\ survival\\ than\\ in\\ patients\\ with\\ unilateral\\ breast\\ cancer\\ \\(ubc\\)\\.\\ \\ \\ patients\\ with\\ bbc\\ showed\\ a\\ higher\\ proportion\\ of\\ tubular\\ carcinoma\\ and\\ medially\\ located\\ tumors\\,\\ a\\ greater\\ 5\\-\\ and\\ 10\\-year\\ local\\ recurrence\\ rate\\ and\\ nearly\\ double\\ the\\ 5\\-\\ and\\ 10\\-year\\ distant\\ metastasis\\ rate\\.\ \(0\)\
\-\ as\\ synchronous\\ breast\\ carcinoma\\ represents\\ a\\ minority\\ of\\ cases\\ \\(1\\.5\\%\\)\\,\\ it\\â\\€\\™s\\ optimal\\ management\\ continues\\ to\\ be\\ under\\ debate\\.\ \(0\)\
\-\ \\*synchronous\\,\\ bilateral\\ breast\\ cancer\\:\\ prognostic\\ value\\ and\\ incidence\\,\\ \\ the\\ breast\\,\\ volume\\ 12\\,\\ issue\\ 2\\ \\,\\ april\\ 2003\\,\\ pages\\ 83\\-88\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ breast\\:\\ 0\\.41735557460366657\ \(0\)\
\-\ synchronous\\:\\ 0\\.30316375425273767\ \(0\)\
\-\ carcinoma\\:\\ 0\\.2578351829861772\ \(0\)\
\-\ cancer\\:\\ 0\\.239258664424308\ \(0\)\
\-\ bilateral\\:\\ 0\\.23166267562294227\ \(0\)\
\-\ bbc\\:\\ 0\\.22978142535220908\ \(0\)\
\-\ situ\\:\\ 0\\.15994442709441273\ \(0\)\
\-\ mastectomy\\:\\ 0\\.15250216436154013\ \(0\)\
\-\ in\\:\\ 0\\.12510339548075364\ \(0\)\
\-\ patients\\:\\ 0\\.12124486095531097\ \(0\)\
\-\ and\\:\\ 0\\.11876186294470831\ \(0\)\
\-\ the\\:\\ 0\\.1146803725185149\ \(0\)\
\-\ netherlands\\:\\ 0\\.1097842095331371\ \(0\)\
\-\ rate\\:\\ 0\\.10887939566473827\ \(0\)\
\-\ conserving\\:\\ 0\\.10616108789388\ \(0\)\
\-\ ubc\\:\\ 0\\.10105458475091256\ \(0\)\
\-\ minority\\:\\ 0\\.10105458475091256\ \(0\)\
\-\ debate\\:\\ 0\\.09462115163643241\ \(0\)\
\-\ proportion\\:\\ 0\\.09342079746786178\ \(0\)\
\-\ pages\\:\\ 0\\.09342079746786178\ \(0\)\
\-\ optimal\\:\\ 0\\.08951464849346495\ \(0\)\
\-\ elected\\:\\ 0\\.08870183832943092\ \(0\)\
\-\ april\\:\\ 0\\.08793832054292819\ \(0\)\
\-\ recommendation\\:\\ 0\\.08721845682572056\ \(0\)\
\-\ issue\\:\\ 0\\.08589152685420787\ \(0\)\
\-\ prognostic\\:\\ 0\\.08413133890280566\ \(0\)\
\-\ both\\:\\ 0\\.0801250567445545\ \(0\)\
\-\ advised\\:\\ 0\\.07997221354720636\ \(0\)\
\-\ breasts\\:\\ 0\\.07848883204349602\ \(0\)\
\-\ distant\\:\\ 0\\.07513086096365582\ \(0\)\
\-\ diagnosis\\:\\ 0\\.07448458219232086\ \(0\)\
\-\ medially\\:\\ 0\\.07338232890052858\ \(0\)\
\-\ value\\:\\ 0\\.07315123642818963\ \(0\)\
\-\ lobular\\:\\ 0\\.07292430801156134\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.07270139623868649\ \(0\)\
\-\ nearly\\:\\ 0\\.07164243778894588\ \(0\)\
\-\ of\\:\\ 0\\.07029563245612439\ \(0\)\
\-\ survival\\:\\ 0\\.07011399653633829\ \(0\)\
\-\ continues\\:\\ 0\\.06859069681733228\ \(0\)\
\-\ papillary\\:\\ 0\\.06694889578604843\ \(0\)\
\-\ unilateral\\:\\ 0\\.06574854161747778\ \(0\)\
\-\ higher\\:\\ 0\\.06524969674987299\ \(0\)\
\-\ 2003\\:\\ 0\\.06465270411830402\ \(0\)\
\-\ represents\\:\\ 0\\.0641946832293368\ \(0\)\
\-\ double\\:\\ 0\\.06332577414679132\ \(0\)\
\-\ ductal\\:\\ 0\\.06322125747739446\ \(0\)\
\-\ prognosis\\:\\ 0\\.06322125747739446\ \(0\)\
\-\ volume\\:\\ 0\\.06311760103725117\ \(0\)\
\-\ period\\:\\ 0\\.06281165433931267\ \(0\)\
\-\ despite\\:\\ 0\\.06251296398275728\ \(0\)\
\-\ tubular\\:\\ 0\\.06241495425557808\ \(0\)\
\-\ local\\:\\ 0\\.06184239264308097\ \(0\)\
\-\ incidence\\:\\ 0\\.06184239264308097\ \(0\)\
\-\ worse\\:\\ 0\\.06018401758554311\ \(0\)\
\-\ under\\:\\ 0\\.059468698045322246\ \(0\)\
\-\ recurrence\\:\\ 0\\.05931510850299765\ \(0\)\
\-\ pathologic\\:\\ 0\\.05886526831349449\ \(0\)\
\-\ as\\:\\ 0\\.05772281882406972\ \(0\)\
\-\ same\\:\\ 0\\.0568295270049325\ \(0\)\
\-\ located\\:\\ 0\\.0568295270049325\ \(0\)\
\-\ with\\:\\ 0\\.056270107263813124\ \(0\)\
\-\ circumscribed\\:\\ 0\\.05563487027431569\ \(0\)\
\-\ management\\:\\ 0\\.053066208893293984\ \(0\)\
\-\ greater\\:\\ 0\\.05292755589966743\ \(0\)\
\-\ tumors\\:\\ 0\\.05283596141316457\ \(0\)\
\-\ metastasis\\:\\ 0\\.052654746971889196\ \(0\)\
\-\ calcifications\\:\\ 0\\.05243183519901435\ \(0\)\
\-\ based\\:\\ 0\\.05204027455072432\ \(0\)\
\-\ diagnosed\\:\\ 0\\.05204027455072432\ \(0\)\
\-\ above\\:\\ 0\\.051827888634193166\ \(0\)\
\-\ defined\\:\\ 0\\.05125158348703756\ \(0\)\
\-\ or\\:\\ 0\\.04998498095209139\ \(0\)\
\-\ side\\:\\ 0\\.04963036485183576\ \(0\)\
\-\ 12\\:\\ 0\\.0491105860074692\ \(0\)\
\-\ left\\:\\ 0\\.04901362440544988\ \(0\)\
\-\ masses\\:\\ 0\\.048908535903075104\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.048908535903075104\ \(0\)\
\-\ recent\\:\\ 0\\.048644081328095515\ \(0\)\
\-\ first\\:\\ 0\\.04848157344262793\ \(0\)\
\-\ cases\\:\\ 0\\.04832113577766013\ \(0\)\
\-\ study\\:\\ 0\\.04791331827106256\ \(0\)\
\-\ showed\\:\\ 0\\.047851732884861595\ \(0\)\
\-\ primary\\:\\ 0\\.044174969969091725\ \(0\)\
\-\ on\\:\\ 0\\.043394926509287585\ \(0\)\
\-\ time\\:\\ 0\\.042582459316190736\ \(0\)\
\-\ months\\:\\ 0\\.04181775244538535\ \(0\)\
\-\ therapy\\:\\ 0\\.04127778592532835\ \(0\)\
\-\ than\\:\\ 0\\.04072508608720333\ \(0\)\
\-\ metastatic\\:\\ 0\\.039401645293267215\ \(0\)\
\-\ associated\\:\\ 0\\.03786602735472875\ \(0\)\
\-\ tumor\\:\\ 0\\.037577440899489\ \(0\)\
\-\ it\\:\\ 0\\.036774824330816906\ \(0\)\
\-\ case\\:\\ 0\\.03609254993495319\ \(0\)\
\-\ to\\:\\ 0\\.03592062853949253\ \(0\)\
\-\ have\\:\\ 0\\.03588893050344208\ \(0\)\
\-\ had\\:\\ 0\\.03579423692664377\ \(0\)\
\-\ within\\:\\ 0\\.03308812766316081\ \(0\)\
\-\ has\\:\\ 0\\.03281525079109897\ \(0\)\
\-\ be\\:\\ 0\\.02914335492508602\ \(0\)\
\-\ mass\\:\\ 0\\.027441658000136353\ \(0\)\
\-\ at\\:\\ 0\\.027135565494805926\ \(0\)\
\-\ was\\:\\ 0\\.025037586079206028\ \(0\)\
\-\ right\\:\\ 0\\.02381853636087926\ \(0\)\
\-\ patient\\:\\ 0\\.023366538010701397\ \(0\)\
\-\ for\\:\\ 0\\.021774704750256446\ \(0\)\
\-\ is\\:\\ 0\\.019674370926606424\ \(0\)\
